Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
for B Acute Lymphoblastic Leukemia
203 locations incl. Birmingham
Sponsor: Children's Oncology Group
Sex: All·Age: 365 Days - 25
Code: NCT03959085·Phase 3·Recruiting